Spironolactone’s Role in Heart Failure: A Cloudy Outlook Despite New Trial Data
Recent findings from the SPIRIT-HF trial, presented at the American College of Cardiology (ACC) 2026 Scientific Session, have left the medical community pondering the effectiveness of spironolactone in treating heart failure with preserved or mildly reduced ejection fraction (HFpEF and HFmrEF). While the drug didn’t demonstrate a significant improvement in outcomes, the study’s limitations raise questions about whether spironolactone’s potential remains untapped.
The SPIRIT-HF Trial: A Glance at the Results
The SPIRIT-HF trial, conducted across four European countries between 2018 and 2024, involved 730 patients with symptomatic HFpEF or HFmrEF. Participants were randomly assigned to receive either spironolactone or a placebo. After two years, there was no statistically significant difference between the groups in terms of heart failure hospitalizations or cardiovascular death. Specifically, the rate of these events was 10.8 per 100 patient-years in the placebo group and 12.7 in the spironolactone group.
However, the study revealed a significantly higher rate of total hospitalizations, hypotension, renal events, and elevated potassium levels in patients taking spironolactone compared to those receiving a placebo. This suggests potential safety concerns that clinicians must carefully consider.
Underpowered and Interrupted: Why the Results Are Not Definitive
Researchers emphasize that the SPIRIT-HF trial was “underpowered,” meaning it didn’t enroll enough patients to definitively answer the question of spironolactone’s efficacy. The trial aimed for 1,564 participants but only randomized 730. This was largely due to disruptions caused by the COVID-19 pandemic, which impacted funding and enrollment.
a substantial number of patients discontinued spironolactone treatment, potentially due to side effects. An on-treatment analysis, which excluded data from patients who stopped taking the medication, showed a more favorable trend for spironolactone, but this analysis is less conclusive.
The Ongoing Search for Answers: SPIRRIT and Beyond
Despite the inconclusive results of SPIRIT-HF, the search for effective treatments for HFpEF and HFmrEF continues. The ongoing SPIRRIT trial, a registry-based study in Sweden and the United States, aims to enroll 2,000 patients and may provide more definitive answers.
The earlier TOPCAT trial offered mixed signals, with a potential benefit observed in the Americas cohort. Researchers are also exploring other mineralocorticoid receptor antagonists (MRAs), such as finerenone, which has shown promise in reducing heart failure events and cardiovascular death in patients with HFmrEF and HFpEF in the FINEARTS-HF trial.
Nonsteroidal MRAs: A Potential Alternative?
The contrasting results between steroidal MRAs like spironolactone and nonsteroidal MRAs like finerenone are prompting further investigation. Experts suggest that the different mechanisms of action and side effect profiles of these drugs may contribute to the observed differences in efficacy.
Biykem Bozkurt, MD, PhD, commented that the verdict is still out on whether nonsteroidal MRAs are differentially effective compared to steroidal MRAs, highlighting the require for continued research.
Future Trends and Considerations
The future of heart failure treatment likely involves a more personalized approach, taking into account individual patient characteristics and risk factors. Further research is needed to identify which patients with HFpEF and HFmrEF are most likely to benefit from MRA therapy, and whether steroidal or nonsteroidal MRAs are the preferred choice.
The development of new biomarkers and imaging techniques may also aid to identify patients who are more likely to respond to specific treatments. Ongoing trials are exploring the potential of combination therapies that target multiple pathways involved in heart failure progression.
Frequently Asked Questions
Q: What is spironolactone?
A: Spironolactone is a mineralocorticoid receptor antagonist (MRA) that helps to block the effects of aldosterone, a hormone that can contribute to heart failure.
Q: What are HFpEF and HFmrEF?
A: HFpEF stands for heart failure with preserved ejection fraction, and HFmrEF stands for heart failure with mildly reduced ejection fraction. These conditions involve heart failure symptoms with different levels of heart muscle pumping ability.
Q: Why was the SPIRIT-HF trial inconclusive?
A: The trial was underpowered due to lower-than-planned enrollment, and a significant number of patients discontinued treatment, limiting the ability to draw definitive conclusions.
Q: What is the SPIRRIT trial?
A: SPIRRIT is an ongoing registry-based trial in Sweden and the United States that aims to enroll 2,000 patients with HFpEF to further investigate the role of spironolactone.
Q: Are there other medications besides spironolactone for HFpEF and HFmrEF?
A: Yes, finerenone, a nonsteroidal MRA, has shown promise in recent trials, and other therapies are being investigated.
Did you know? The COVID-19 pandemic significantly impacted clinical trial enrollment across the globe, delaying research and potentially affecting the results of studies like SPIRIT-HF.
Pro Tip: If you have been diagnosed with heart failure, it’s crucial to work closely with your healthcare provider to develop a personalized treatment plan that addresses your specific needs and risk factors.
Stay informed about the latest advancements in heart failure treatment by exploring our other articles on cardiovascular health. Read more here.
Keep reading